Carver Biosciences Launches With Seed Financing To Advance Crispr/Cas13-Based Technologies
Round Type
Seed
BostonBiotechnologyHealth CareTherapeuticsDescription
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the closure of a seed round of funding, led by Khosla Ventures.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Carver that raised within 45 days of this round, from Fundz verified event records.
- Biofrontera raised $3.7M (Seed) on October 25, 2022.
- MapLight Therapeutics raised $12M on October 25, 2022.
- Insmed Incorporated raised an undisclosed amount (Funding Round) on October 19, 2022.
- Orionis Biosciences raised $55M (Funding Round) on October 19, 2022.
- SURGE Therapeutics raised $26M (Series A) on October 17, 2022.
- Mablink Bioscience raised $30M (Series A) on October 14, 2022.
Who to call at Carver, and when
A new round usually means Carver is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Carver raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Carver, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Carver. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Carver raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Carver raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.